work, the molecular targets to be affected by antiarrhythmic drugs (ion channels, receptors, and pumps) are listed on the left side, with the corresponding clinical effects of the drugs (heart rate, electrocardiographic intervals, ventricular performance, and side-effect potential) appearing on the right side of the columns. 3 The antiarrhythmic drugs are listed in vertical rows in order of their predominant molecular targets.
The spreadsheet (Gambit framework) has the following advantages.
(1) It does not discard useful information about a drug. Most antiarrhythmic drugs act at several sites, sharing a spectrum of action with other agents. Such multifaceted drug actions can be presented appropriately. ( 2) The listing is flexible. The vertical order of the antiarrhythmic drugs may be changed to emphasize different drug clusters. For example, drugs that act atreceptors or those that block potassium channels can be placed together. If important new molecular targets are found in future basic research, they can be added as new columns. As new effective antiarrhythmic drugs are developed, they would be added by expanding rows. ( 3) The tabular approach is suitable for programming diverse drug information into computer software for availability from single channel, single cell to bedside. From April to December 1996, members of the Guideline Committee met 4 times to discuss pharmacologic profiles of 4 antiarrhythmic drugs (aprindine, cibenzoline, pilsicainide, and pirmenol) that were not included in the original spreadsheet but used widely in clinical practice in Japan. The discussion aimed to fit the drug profiles into the Gambit framework based on all the important literature published to date regarding the actions of the 4 drugs in experimental as well as clinical studies. This report is a summary of that deliberation.
Aprindine

Action Potentials
Aprindine causes a decrease in the maximum upstroke velocity (Vmax) of action potentials without affecting the resting membrane potential. This action occurs in cardiac tissues and cells whose excitation depends on activation of the fast sodium channel. Verdonck et al 5 and Carmeliet and Verdonck 6 demonstrated concentration-dependent decreases in Vmax in cow and dog Purkinje fibers upon treatment with aprindine (half-maximal inhibitory concentration on IC50, 2 mol/L), in association with marked shortening of the action potential duration (APD). They also showed a concentration-dependent, aprindine-induced decrease in Vmax in atrial and ventricular muscles from guinea pigs, cats and cows, but this inhibition was less prominent than in Purkinje fibers; APD of atrial and ventricular muscles were slightly shortened or unaffected. 5, 6 Qualitatively similar results were obtained by other investigators in cardiac tissues from guinea pigs or rabbits. [7] [8] [9] [10] [11] Aprindine-induced Vmax inhibition is enhanced in a frequency-and use-dependent manner. 5, 7, 9, 10, [12] [13] [14] [15] [16] The onset and offset kinetics of use-dependent Vmax inhibition are intermediate. 9, 10, [12] [13] [14] [15] The recovery time constants ( R) of Vmax from use-dependent blockade reported in ventricular muscle or cells ranged from 3 to 8 s. 9, 10, 13, 14, 17 Comparable values were reported for atrial muscle. 15 Kodama et al examined the voltage-and time-dependence of Vmax inhibition by aprindine in papillary muscles and in ventricular myocytes isolated from guinea pig hearts using single-sucrose gap or whole-cell voltage-clamp techniques. 13, 18, 19 In ventricular muscles or myocytes treated with aprindine (2-5 mol/L), application of conditioning depolarization to 0 mV from a holding potential (HP) at resting level (-80 to -90 mV) caused a decrease in Vmax of a test action potential elicited 100 ms after the clamp pulse. This decrease became more marked as clamp pulse duration was prolonged. 13, 18, 19 These authors estimated the extent of sodium channel block by various antiarrhythmic drugs, including aprindine, during activated and inactivated states. 18, 19 A percentage decrease in Vmax by the shortest clamp pulse (10 ms) from the reference level (tonic blockade subtracted value) was defined as an activated channel blockade (ACB), while an additional percentage decrease in Vmax occurring when clamp pulse duration was prolonged from 10 to 500 ms was defined as an inactivated channel blockade (ICB). Blockade of sodium channels during slow inactivation can be neglected in this definition, because Vmax of control muscles or myocytes decreased significantly only when the conditioning 0 mV clamp was maintained for longer than 500 ms. 18, 19 ACB and ICB induced by 2-5 mol/L aprindine were estimated to be 1.3-5.4% and 14.6-49.6%, respectively, giving rise to a ratio (ICB/ACB) of 7.4-11.2. 13, 18, 19 In single-cell experiments, ICB/ACB ratios for aprindine, mexiletine, and lidocaine were all larger than 5.0, while those for quinidine and disopyramide were much less (1.5-1.6). 18, 19 The authors therefore concluded that aprindine appears to block the sodium channel mainly during the inactivated state.
In ventricular muscles or cells treated with aprindine, additional application of lidocaine or mexiletine has been demonstrated to cause an increase in tonic blockade, but a decrease of use-dependent blockade, often resulting in a net increase in Vmax at certain stimulation rates. 10, 13, 14, 20 In the presence of both aprindine and lidocaine (or mexiletine), Vmax recovered from use-dependent blockade according to a dual exponential function, where the short-and long-time constants corresponded to the values for single treatments with each drug. 10, 13, 14 These findings suggest that aprindine, lidocaine, and mexiletine may block the sodium channel by binding with different kinetics to a common receptor site, leading to competitive displacement of one another at high concentrations. 13, 21 In support of this hypothesis, Lee et al have demonstrated that additional application of lidocaine attenuated the frequency-dependent QRS prolongation induced by aprindine in ECGs obtained from patients with implanted pacemakers. 22 As for effects on cardiac action potentials that depend on activation of calcium channels, Carmeliet and Verdonck, 6 and Elharrar et al 23 have reported that aprindine (3-10 mol/L) did not affect slow action potentials of K + -depolarized ventricular muscles or Purkinje fibers. These groups therefore suggested that aprindine may lack slow channel blocking properties. However, in experiments using small sinoatrial (SA) node tissue specimens isolated from rabbit hearts, Kotake et al found that aprindine (1-4 mol/L) caused significant concentration-dependent decreases in Vmax, in the amplitude of action potentials, and in their spontaneous firing rate. 24 Aprindine (1 mol/L) also was shown to reduce Vmax and amplitude of action potentials as well as spontaneous firing rate in small atrioventricular (AV) node tissue specimens isolated from rabbit hearts. 25 
Ionic Currents
Sato et al examined the effects of aprindine on the inward sodium current (iNa) in single guinea-pig ventricular myocytes using whole-cell voltage-clamp techniques. 26 Aprindine (3 mol/L) caused both tonic and phasic (usedependent) inhibition of iNa. The IC50 of aprindine for tonic blockade was 37.7 mol/L at an HP of -140 mV, and 0.74 mol/L at an HP of -100 mV. Aprindine (3 mol/L) shifted the steady-state inactivation curve of iNa in the hyperpolarizing direction by 11.4 mV. Phasic block of iNa by aprindine (3 mol/L) in response to 2-Hz trains of depolarization to -20 mV from an HP at -140 mV was enhanced moderately as the duration of each depolarization was prolonged from 1.5 to 200 ms. The R from aprindineinduced phasic blockade was 5.0 s These authors also showed that aprindine-induced phasic blockade of iNa persisted after pharmacologic removal of rapid inactivation, finally concluding that aprindine blocks iNa at least partially by binding to channels in the activated state. Discordance of this conclusion with the Vmax measurement studies described before 11, 13, 19 could result from different experimental conditions such as low temperature and low external sodium concentrations in the iNa experiments.
Aprindine has been shown to inhibit the slow inward current (isi) in multicellular tissue preparations of rabbit SA and AV nodes. 24, 25 In SA node cells, aprindine (4 mol/L) reduced isi by approximately 20%, 24 whereas the IC50 of aprindine for isi inhibition in AV node cells was approximately 10 mol/L. 25 Aprindine-induced isi inhibition in AV node cells was enhanced in voltage-and use-dependent manners, suggesting a higher affinity of this compound for Ca 2+ channels in the inactivated than the resting state. 25 In whole-cell voltage-clamp experiments on guinea pig atrial cells, Shibasaki et al demonstrated that 5 mol/L aprindine reduced inward calcium current (iCa) by 35%. 27 In double-microelectrode voltage-clamp experiments on rabbit SA and AV node preparations, aprindine (1-4 mol/ L) caused a moderate reduction of the delayed rectifier K + current (iK) and the hyperpolarization-activated inward current (the pacemaker current, if). 24, 25 Aprindine (5 mol/ L) also reduced iK in single guinea pig atrial cells without affecting the inward rectifier K + current (iK1). 27 However, relatively little is known and much remains to be investigated as to the effects of aprindine on these ionic currents.
Receptors and Pumps
Aprindine does not possess anticholinergic properties. 25, 28, 29 No in vivo or in vitro experimental data suggest direct effects of aprindine on -and -adrenergic receptors, adenosine (A1) receptors, or sarcolemmal Na/K pumps. 25, 28, 29 Aprindine at high concentrations has been shown to interfere with calmodulin activation of such cytosolic enzymes as phosphodiesterase and Ca 2+ -ATPase. 30, 31 The pharmacologic significance of this calmodulin inhibition is still unsettled.
Clinical Effects
Since its development in Belgium in 1973, aprindine has been used clinically in 7 European countries. However, clinical investigation of the drug was halted in the United States due to such side-effects as agranulocytosis. In Japan, lower doses of aprindine have been recognized as effective and safe for supraventricular and ventricular arrhythmias.
Effects on the Various Tachyarrhythmias (1) Supraventricular premature contractions (SVPC) and ventricular premature contractions (VPC). In a randomized study by Pouleur et al in which aprindine (80 mg/day), disopyramide (400 mg/day), or a placebo was given to patients with ventricular arrhythmias, aprindine was significantly more effective (p<0.05) than disopyramide or placebo. 32 In a double-blind comparison of the effect of aprindine (60 mg/day) and disopyramide (300 mg/day) on VPC and SVPC, aprindine proved to be significantly more effective. 33 (2) Paroxysmal supraventricular tachycardia (PSVT). [34] [35] [36] [37] Intravenous administration of aprindine (100 mg; with a maximum dosage, 2 mg/kg) was highly effective in terminating AV reciprocal tachycardia and AV nodal reentrant tachycardia, with a success rate of 70-100%. In contrast, aprindine failed to convert paroxysmal atrial fibrillation to sinus rhythm in 15 of 22 cases. Oral aprindine prevented induction of PSVT by programmed stimulation in only 2 of 21 cases. (3) Mortality reduction. Two double-blind, randomized, placebo-controlled trials were conducted to determine whether aprindine influences mortality in highrisk patients after acute myocardial infarction. According to Gottlieb et al, aprindine reduced mortality at 1 month, but had no effect on overall mortality or sudden death rates at 1 year. 38 The Ghen-Rotterdam aprindine study reported that aprindine tended to be effective in reducing mortality. 39, 40 Clinical Electrophysiology and Effects on Cardiac Function Aprindine prolonged the AH and HV intervals and the effective refractory periods of the atrium, ventricle and AV node, 35 and suppressed antegrade and retrograde conduction in Kent's bundle while prolonging its effective refractory period. 35 On the ECG, aprindine increased PQ, QRS, and QT intervals. The PP interval did not change, but occurrence of sinus arrest has been reported in patients with sick sinus syndrome.
Oral administration of aprindine did not decrease contractility, 41 but aprindine given intravenously produced a moderate, dose-related decrease in peak left ventricular (LV) dP/dt and Vmax. 42 Clinical Pharmacology and Side-Effects While in the United States and Europe the appropriate daily dose of aprindine is in the range of 100-150 mg with an effective serum concentration of 1-2 g/ml, 43 in Japan the dose is only 40-60 mg and the serum concentration is only 0.13-0.68 g/ml. 44 The difference may be related to a racial difference in sensitivity to aprindine. Aprindine is metabolized exclusively by the liver, mainly by the enzyme CYP206, 45 and thus may cause a drug interaction with diltiazem by competing for CYP206. The pharmacokinetics of aprindine are nonlinear. 44 The major side-effects of aprindine include agranulocytosis and cholestatic jaundice, which are thought to be idiosyncratic reactions. Agranulocytosis was reported rarely in the United States (3 of 400-500 patients). The incidence of agranulocytosis is estimated as approximately 2 occurrences per 1000 patient-years based on data from Europe. 46 Other reported side-effects included neuralgia and seizures, which were related to the dose and serum concentration of aprindine.
Gambit Profile
The pharmacologic profile of aprindine can be summarized as follows (Table 1) . First, aprindine has a potent usedependent inhibitory action on the cardiac sodium channel. From the onset and offset kinetics of use-dependent blockade, aprindine belongs among the intermediate-kinetic drugs, and it appears to block the sodium channel mainly during the inactivated state. Second, aprindine may have modest inhibitory actions on Ca 2+ and K + channels and the if channel, but the effects of aprindine on these ionic channels have not yet been thoroughly investigated. Finally, aprindine has no significant effects on -, -, or A1-receptors, or on Na/K pumps.
Cibenzoline
Action Potentials
In atrial and ventricular muscles as well as in Purkinje fibers from rabbits and dogs, Millar and Vaughan Williams 47, 48 and Dangman 49 demonstrated that cibenzoline (1-20 mol/L) decreased Vmax without affecting the resting membrane potential. Similar concentration-dependent Vmax inhibition by cibenzoline was observed in guinea pig ventricular muscle. 50, 51 The IC50 of cibenzoline for Vmax inhibition in those studies was 2-10 mol/L. Cibenzolineinduced Vmax inhibition became more pronounced in a frequency-and use-dependent manner. 50, 51 The onset and offset kinetics of use-dependent Vmax inhibition with cibenzoline are slow. 50, 51 The R of Vmax from use-dependent block in guinea pig papillary muscles was assigned a value of 26.2 s by Niwa et al. 51 Niwa et al also examined the voltage-and time-dependence of Vmax inhibition by cibenzoline in single guinea pig ventricular cells using whole-cell clamp techniques. 51 In myocytes treated with cibenzoline (10 mol/L), application of the shortest (10 ms) single conditioning depolarization to 0 mV from an HP at -80 mV caused substantial Vmax reduction of a test action potential elicited 100 ms after a 10-ms depolarization. Vmax inhibition was enhanced modestly by further prolongation of clamp pulse duration. These authors evaluated the approximate extent of sodium channel block during activated and inactivated states using the definition of Kodama et al 18, 19 with average values for ACB and ICB by 10 mol/L cibenzoline being 11.0% and 16.4%, respectively; the resulting ICB/ACB ratio of 1.5 is comparable to that for quinidine (1.6) and disopyramide (1.3). 51 In guinea pig ventricular myocytes treated with 3 mol/L cibenzoline, use-dependent Vmax reduction during a train of 0 mV depolarization was enhanced only slightly by a prolongation of each depolarization from 10 to 200 ms. 51 These observations suggest that cibenzoline may block the sodium channel mainly during the activated state.
Reports of cibenzoline effects at 1-10 mol/L on APD are conflicting. APD of atrial and ventricular muscles from rabbits or dogs were moderately prolonged, while the APD of dog Purkinje fibers was shortened. [47] [48] [49] [50] APD in rabbit Purkinje fibers and guinea pig papillary muscles was unaffected by cibenzoline. 47, 48, 51 This discrepancy could be a result of differences in ionic currents responsible for repolarization of the action potential in different cardiac tissues and animal species. 52 Only limited information is available regarding the effects of cibenzoline on cardiac tissues whose excitation depends on activation of slow calcium channels. In SA node preparations isolated from rabbits, cibenzoline (1-30 mol/L) was shown to cause concentration-dependent decreases in Vmax, action potential amplitude, and rate of spontaneous excitation. 47, 48, 53 
Ionic Currents
An inhibitory effect of cibenzoline on the iNa was demonstrated in frog atrial muscles using the double sucrose-gap voltage-clamp method, 54 and in single guinea pig ventricular myocytes using the whole-cell voltageclamp method. 55 The IC50 of cibenzoline for iNa in guinea pig ventricular myocytes was estimated as 7.8 mol/L. 55 The effects of cibenzoline on iNa kinetics and the use-and voltage-dependence of iNa inhibition by cibenzoline have not been investigated.
In whole-cell voltage-clamp experiments using guinea pig ventricular myocytes, cibenzoline (1-30 mol/L) was shown to inhibit iCa in a concentration-dependent manner. [55] [56] [57] The IC50 of cibenzoline for iCa as estimated by Holk and Osterrieder 56 and by Sato et al 55 was approximately 14 mol/L, but a higher value (30 mol/L) was reported by Matsuoka et al. 57 This iCa inhibition was enhanced at higher depolarization frequencies and at more positive HP. 56 Inhibition of iCa by cibenzoline also was demonstrated in frog atrial muscles using double sucrose gap voltage-clamp methods 54 and in rabbit SA node preparations using a double-microelectrode voltage-clamp method. 53 Cibenzoline inhibits voltage-dependent K + channel currents. Sato et al demonstrated concentration-dependent inhibition of both the iK and the iK1 in guinea pig ventricular myocytes with respective IC50 at 23.0 mol/L and 33.7 mol/L. 55 In rabbit SA node cells, iK also was shown to be decreased by about 30% after application of 30 mol/L cibenzoline. 53 A recent study by Wang et al indicated that both a rapidly activating, E-4031-sensitive component of iK (iKr) and a slowly activating, E-4031-insensitive component of iK (iKs) are inhibited by cibenzoline. 58 Cibenzoline inhibits ligand-gated K + channel currents as 47 In experiments by Niwa et al, however, cibenzoline (10 mol/L), unlike glibenclamide, failed to prevent hypoxia-induced APD shortening of guinea pig ventricular muscle. 51 Therefore, the pharmacologic importance of iK,ATP inhibition as an action of cibenzoline is still unclear. Effects of cibenzoline on the muscarinic receptor-activated, acetylcholine (ACh)-sensitive K + channel current (iK,ACh) were examined by Wu et al in guinea pig atrial myocytes using a whole-cell voltage clamp method. 61 They showed a concentration-dependent inhibition of iK,ACh by cibenzoline with IC50 at 8 mol/L. This cibenzoline action is most likely to be mediated by inhibition of the AChsensitive K + channel itself and/or GTP-binding proteins coupled to the channel. 61 
Receptors and Pumps
Cibenzoline has anticholinergic effects. Cazes et al compared the anticholinergic effects of cibenzoline with those of disopyramide in vitro and in vivo animal experiments. 62 Respective Ki values for inhibition of specific binding of 3 H-quinuclidinyl benzylate ( 3 H-QNB) of cibenzoline and disopyramide were 15.8 mol/L and 12.0 mol/L in a rat heart membrane preparation, and 31.6 mol/L and 7.8 mol/L in cerebral cortical membranes. 62 In isolated guinea pig ileum, disopyramide was about 15 times more strongly anticholinergic than cibenzoline. 62 According to antagonism of the negative chronotropic effect of vagal stimulation in anesthetized dogs, intravenously administered cibenzoline was shown to be several times less potent than disopyramide. 62 Cibenzoline may not affect cardiac sympathetic -receptors, because it does not inhibit the positive chronotropic effect of isoproterenol on isolated rabbit SA node tissue preparations or dog Purkinje fibers. 47, 49 No reports to date have shown significant effects of cibenzoline on -adrenergic receptors, A1 receptors, or sarcolemmal Na/K pumps in the heart.
Clinical Effects
Several studies have investigated the electrophysiologic effects of cibenzoline in patients with various arrhythmias. 63 Touboul et al have reported dose-dependent increases in QRS, QT, AH, and HV intervals, and in the ventricular effective refractory period (ERP) over an intravenous dose range of 1.55-2.6 mg/kg. 64 Prolongation of QRS and HV intervals reflecting intraventricular conduction delay was observed at relatively low doses of cibenzoline (1.55-1.8 mg/kg), whereas prolongation of the AH interval reflecting conduction delay in the AV node was observed at higher doses. 64 The JT interval was unaltered, suggesting that the increased QRS duration alone accounted for the increase in the QT interval. 64 Cibenzoline has inconsistent effects on sinus rate in patients; 63 when given orally, cibenzoline does not affect sinus rate significantly, 65 but this drug increases sinus rate slightly when given intravenously. 66 The direct inhibitory effect of cibenzoline on the SA node possibly counteracts any clinically significant reflex tachycardia in response to the negative inotropic effect of this compound, minimizing changes in heart rate. 63 Cibenzoline exerts a negative inotropic effect following single-dose intravenous administration, causing significant transient decreases in ejection fraction (EF), cardiac index, stroke volume index, maximum velocity of contractile shortening, and rate of change of LV pressure, accompanied by an increase in vascular resistance, within the therapeutic range for plasma concentration (250-350 g/L). 63 Effects on blood pressure are minimal. 63 A comparative study indicated that the negative inotropic effects of cibenzoline at doses 1.0 and 1.2 mg/kg (iv) were similar to those of disopyramide at 2 mg/kg in patients with coronary artery disease. 66 Oral cibenzoline (5 mg day -1 kg -1 ) was shown to have no significant effects on left ventricular function. 63 Cibenzoline has been relatively well tolerated in clinical trials. 63 As for extracardiac side-effects, gastrointestinal disturbances, nervousness and tremulousness, and to a lesser extent blurred vision, dry mouth, and urinary retention have been observed. Some of these adverse effects are attributable to the anticholinergic properties of cibenzoline. The compound also sporadically induces hypoglycemia, probably due to inhibition of KATP channels in pancreatic cells. [67] [68] [69] Gambit Profile (Table 1) First, cibenzoline has a potent use-dependent inhibitory action on the cardiac sodium channel. From the onset and offset kinetics of use-dependent blockade, cibenzoline is among the slow-kinetic drugs, and it may block the sodium channel mainly during the activated state. Second, cibenzoline has inhibitory actions on Ca 2+ channels (relatively weak) and K + channels (moderately potent). The K + channels affected by cibenzoline include both voltage-dependent channels (iK, and iK1) and ligand-gated channels (iK,ATP and iK,ACh). Third, cibenzoline has anticholinergic effects, but has no effects on other receptors or on pumps. Fourth, cibenzoline inhibits LV function of patients at therapeutic doses, but has no consistent effects on sinus rate. Extracardiac side-effects of cibenzoline are relatively weak, but in some patients hypoglycemia may occur. Finally, in clinical ECG, cibenzoline prolongs PR and QRS intervals without affecting the JT interval.
Pilsicainide
Action Potentials
In isolated atrial and ventricular muscles from guinea pigs and Purkinje fibers from dogs, pilsicainide (3-30 mol/L) was shown to cause a concentration-dependent decrease in Vmax without affecting resting membrane potential. [70] [71] [72] [73] Vmax of those tissues constantly stimulated at 1.0 Hz was reduced by 30-50% at 30 mol/L pilsicainide. 70, 71 The APD of Purkinje fibers was shortened by pilsicainde (by 40% at 30 mol/L), while the APD of atrial and ventricular muscle was unaffected. 70, 71 Vmax inhibition was enhanced in a frequency-or use-dependent manner. 72, 73 Onset and offset kinetics of use-dependent Vmax inhibition with Japanese Circulation Journal Vol. 63, January 1999 pilsicainde are relatively slow. 57, 58 As for the R from usedependent blockade, Hattori et al reported a value of 27-28 s in guinea pig papillary muscle. 72 With respect to Ca 2+ channel-dependent slow action potentials, pilsicainide at concentrations up to 30 mol/L showed no significant effects on the slow responses of guinea pig papillary muscles induced by high K + (22 mmol/L) plus isoproterenol (0.2 mol/L). 70 In small tissue specimens of rabbit SA and AV nodes, however, pilsicainde (10-20 mol/L) caused slight decreases in Vmax and amplitude of spontaneous action potentials. 74, 75 
Ionic Currents
Direct evidence for iNa inhibition by pilsicainide was demonstrated in whole-cell voltage-clamp experiments on single ventricular myocytes isolated from rat and guinea pig hearts. 71, [76] [77] [78] Pilsicainide reduced iNa elicited by depolarization pulses (0.1-0.2 Hz) in a concentration-dependent manner with an IC50 of 20-30 mol/L. 71, 76 Inhibition of iNa by pilsicainide included both tonic (resting) and phasic (use-dependent) components with greater use-dependent block of higher depolarization pulse frequencies. 71, [76] [77] [78] Recovery of iNa in the presence of pilsicainide (10-30 mol/ L) followed a double exponential function, most likely reflecting rapid recovery of drug-free Na + channels and slow recovery of drug-associated channels with time constants from 15 to 70 ms and 65-580 ms, respectively. 71, [76] [77] [78] Inomata et al investigated the state-dependence of sodium channel blockade in guinea pig atrial myocytes pretreated with scorpion toxin (5 mol/L), which inhibits inactivation of iNa. 77 Application of pilsicainide (10 mol/L) to these myocytes resulted in a use-dependent decrease in the peak amplitude of the relatively persistent iNa, and this iNa inhibition was associated with an accelerated phase current decay. 77 They suggested from these findings that pilsicainide may interact preferentially with the sodium channel in the open state. 77 The state-dependence of sodium channel block by pilsicainde also was tested in single guinea pig ventricular myocytes using multiple 0-mV conditioning voltage-clamp measurements with an interpulse interval of 500 ms from an HP at -85 mV. 79 Both short (10 ms) and long (200 ms) pulse trains applied to myocytes treated with pilsicainide (10 mol/L) caused a marked use-dependent Vmax reduction with the trains, but the enhancement of Vmax reduction by prolongation of clamp pulse duration was minimal or negligible. 79 This pattern suggests that repetition of the activated state is required for development of use-dependent blockade of iNa by pilsicainide.
Pilsicainide at high concentrations causes minimal to moderate inhibition of ionic currents passing through Ca 2+ and K + channels. 71, 75, 80, 81 Inomata et al compared the potency of iNa and iCa inhibition by pilsicainide in guinea pig ventricular myocytes, and reported IC30 of 9.1 mol/L for iNa and 55 mol/L for iCa. 71 They therefore, suggested that the iCa-blocking action of pilsicainide would be negligible at an effective plasma concentration for treatment of arrhythmias (2-10 mol/L).
In single guinea pig atrial myocytes, iK,ACh was inhibited by pilsicainide in a concentration-dependent manner (IC50, 25-30 mol/L) when the current was activated by external application of ACh; however, the current activated by internal loading with GTPgS was unaffected. 80 In experiments using concentration-clamp techniques, pilsicainide was shown to prolong the latent period of iK,ACh activation upon sudden exposure to ACh. 81 These data suggest that inhibition of iK,ACh by pilsicainide may resemble that by disopyramide, being mediated by blockade of muscarinic (M2) receptors. 80, 81 Pilsicainide had no significant effects on iK,ATP activated by 2,4-dinitrophenol in guinea pig atrial myocytes. 59 No information is available concerning the effect of pilsicainide on if.
Receptors and Pumps
Pilsicainide has a weak inhibitory action on iK,ACh, probably through a blockade of M2 receptors as described before. Unlike that of disopyramide, however, the anticholinergic effect of pilsicainide is minimal or negligible at therapeutic plasma concentrations (2-10 mol/L). 80 Pilsicainide at antiarrhythmic doses has little or no effects on the autonomic nervous system of animals in vivo. 82, 83 Pilsicainide, even at a high concentration (30 mol/L), has no significant effect on ACh-or histamine-induced contractions of isolated guinea pig ileum or tracheal smooth muscle. 83 No reports to date have shown significant effects of pilsicainide on -or -adrenergic receptors, A1 receptors, or sarcolemmal Na/K pumps.
Clinical Effects
Pilsicainide is a novel class I antiarrhythmic agent developed in Japan by the Biomedical Institute of Suntory Limited. Therefore, to date, clinical data regarding this drug have been limited to investigations in Japan. This drug is indicated for supraventricular and ventricular tachyarrhythmias, and is considered highly effective and safe. Pilsicainide for intravenous administration has been developed, and will soon be clinically available.
Effect on the Various Tachyarrhythmias In a doubleblind placebo-controlled comparative study of pilsicainide (150 mg/day) and disopyramide (300 mg/day) on SVPC and VPC, reduction of the respective arrhythmia by 75% or more occurred in 28% and 38% in the disopyramide group, and 52% and 50% in the pilsicainide group. 84, 85 When the pharmacologic effect of pilsicainide on PSVT was evaluated electrophysiologically, induction of PSVT was prevented in 69-86% of cases. [86] [87] [88] In a double-blind, placebo-controlled study investigating the acute effect of pilsicainide on paroxysmal atrial fibrillation, sinus rhythm was restored in 45% of cases after a single oral dose of 150 mg, compared to 9% in the placebo group. 89 Clinical Electrophysiology and Effect on Cardiac Function A single dose of pilsicainide of 150-200 mg significantly prolonged PA, AH and HV intervals, sinoatrial conduction time (SACT), and right ventriclular ERP, but had no influence on sinus node recovery time, ERP of the AV node, functional refractory period of the AV node, or ERP of the right atrium. 86 With regard to effects on electrocardiographic parameters, the QRS and PQ intervals and the P wave width were prolonged in a dose-dependent manner, but no influence was observed on RR or QTc intervals. 84, 85, 88 Adverse Effects and Clinical Pharmacology During postmarketing surveillance, adverse effects of pilsicainide were observed in 4.8% of 3768 cases; including first degree AV block in 0.72%, bundle branch block in 0.56%, and gastrointestinal symptoms in 0.94%. Ventricular tachycardia and ventricular fibrillation were observed in 0.19% and 0.08% of cases, respectively.
Pharmacokinetically, the drug is well fitted by a one-compartment model, exhibiting linear pharmacokinetics with a half-life (T 1 ⁄2) showing a proportional correlation between the dose and both the area under the curve (AUC) and Cmax. Cmax and T 1 ⁄2 were found to be 1-2 and 4-5 h, respectively. Pilsicainide is considered renally excreted; 75-86% of administered drug is excreted through the kidneys. 90, 91 Gambit Profile (Table 1) First, pilsicainide has a potent use-dependent inhibitory action on the cardiac sodium channel. From the onset and offset kinetics of this use-dependent blockade, pilsicainide is a slow-kinetic drug, and it seems to block the sodium channel mainly during the activated state. Second, pilsicainide at therapeutic concentrations has no substantial effects on other ionic channels, receptors, or pumps.
Pirmenol
Action Potentials
In Purkinje fibers of dogs and rabbits constantly stimulated at 0.7-2 Hz, pirmenol (≥1 mol/L) caused a concentration-dependent decrease in Vmax without affecting resting membrane potential (IC50 for Vmax inhibition was about 10 mol/L). [92] [93] [94] [95] The APD of Purkinje fibers at the late repolarization phase was moderately prolonged (3-12%) at relatively low concentrations of pirmenol (1-10 mol/L), but shortened at high concentrations (10-30 mol/L). [92] [93] [94] [95] In rabbit atrial muscles stimulated at 1-2 Hz, Vmax was decreased by 30-40% and APD at late repolarization was prolonged by 10-40% by 5-6 mol/L pirmenol. 94, 96 Pirmenol also was shown to concentration-dependently reduce Vmax in ventricular muscles of guinea pigs and rabbits. [96] [97] [98] [99] [100] [101] IC50 for Vmax inhibition was about 30 mol/L in guinea pig papillary muscles stimulated at 1.0 Hz. 97, 100 APD of the ventricular muscle was slightly prolonged (5-10%) at low concentrations (3-10 mol/L), but shortened at high concentrations of pirmenol (30-100 mol/L). 97, 98, 100, 101 Prolongation of APD (13-30%) by pirmenol (5-10 mol/L) also was reported in single atrial and ventricular myocytes obtained from rabbits. 94, 102 Vmax inhibition by pirmenol in Purkinje fibers and ventricular muscles was enhanced in a frequency-or usedependent manner. 93, 95, [97] [98] [99] [100] Onset and offset kinetics of use-dependent Vmax inhibition are slow. 93, 95, [97] [98] [99] [100] The R of Vmax from use-dependent blockade was reported as 27-34 s in experiments by Nakaya et al using guinea pig papillary muscles. 97, 99, 100 Comparable values (16-18 s) were reported by other investigators in experiments on ventricular muscle or Purkinje fibers. 95, 98 Reichardt et al examined voltageand time-dependence of Vmax inhibition in rabbit Purkinje fibers using a double-microelectrode voltage-clamp method. 93 Application of a single conditioning depolarization to -45 mV from an HP at -105 mV in the presence of pirmenol (50 mol/L) resulted in a significant decrease in Vmax of the test action potential elicited 100 ms after the conditioning clamp. The Vmax reduction consisted of 2 phases; an initial fall with a very short conditioning depolarization (a few milliseconds) was followed by a very slow decline with prolongation of depolarization for up to 2.4 s. 93 In experiments with trains of depolarization to -45 mV from an HP of -105 mV, prolongation of each depolarization from 10 to 500 ms had no significant effect on the extent of use-dependent Vmax inhibiton. 93 From these observations, Reichardt et al concluded that pirmenol may block the sodium channel primarily when it is in the open (activated) state. 93 In guinea pig papillary muscles treated with pirmenol, a partial depolarization of the resting membrane potential resulting from increasing the extracellular K + concentration from 4 to 8 mmol/L resulted in an acceleration of Vmax recovery from use-dependent blockade despite an increase of steady-state amount of blockade. 99 Vmax recovery from use-dependent blockade with lidocaine and mexiletine is known to be accelerated at more negative membrane potentials (hyperpolarization). 103, 104 This has been attributed to a higher affinity for the inactivated state of the sodium channel than the resting state. Under such conditions, hyperpolarization would enhance drug dissociation from channel receptors by increasing the resting fraction of drug-associated channels at the expense of the inactivated fraction. 103, 104 The voltage-dependence of Vmax recovery for pirmenol is opposite to these drugs, and similar to those reported for penticainide, 105 disopyramide, 106 and diprafenone. 102 According to the hypothesis of 'activation trapping' 105,106 the drug molecules, which bind to and unbind from sodium channels primarily during the activated state, are trapped in the channel when it returns to the resting state. Because the probability of having the activation gate in the open position (flicker openings) is smaller at more negative membrane potentials, dissociation of drugs from channel receptors during electrical diastole would be accelerated by depolarization. Dissociation (unbinding) of drugs from the sodium channels during the activation state (activation unblocking) is enhanced by hyperpolarization of the resting membrane potential, 107 leading to a decrease of the steady-state amount of blockade during the stimulation trains. 102, [105] [106] [107] Nevertheless, further experimental studies will be required to substantiate this interpretation.
Disagreement prevails as to effects of pirmenol on action potentials at the SA node. Dukes et al 96 and Sawanobori et al 94 have reported that pirmenol (2-25 mol/L) caused a concentration-dependent prolongation of cycle length of spontaneous excitation in rabbit SA node tissue preparations due to prolongation of repolarization time and a decrease in pacemaker slope, but had no significant effect on Vmax. Kotake et al however, found that pirmenol mol/L) produced a concentration-dependent decrease in Vmax of action potentials in small tissue specimens from the rabbit SA node, in association with prolongation of spontaneous cycle length and APD. 108 No other information is available regarding effects of pirmenol on slow Ca 2+ channel-dependent action potentials.
Ionic Currents
No voltage-clamp studies have been performed to clarify the effects of pirmenol on iNa in cardiac tissues or cells.
Pirmenol (10-30 mol/L) was shown to decrease the amplitude of the slow inward current (isi) in multicellular tissue preparations of rabbit SA nodes in association with slowing of isi recovery from inactivation. 108 In whole-cell voltage-clamp studies on single ventricular and atrial myocytes from rabbit or guinea pig hearts, pirmenol mol/L) decreased the peak amplitude of iCa by 20-22%. 94, 109 As to Ca 2+ channel inhibition by pirmenol, however, information remains very limited, and more extensive voltageclamp studies will be required to assess the pharmacologic significance of this possible action.
Pirmenol inhibits K + -channel currents. In whole-cell voltage clamp experiments on single ventricular myocytes Japanese Circulation Journal Vol. 63, January 1999 from guinea pigs or rabbits, Sawanobori et al have demonstrated that the tail current of iK was decreased by about 30% after application of 5 mol/L pirmenol. 94 A significant inhibition of delayed rectifier outward currents (iK or ix) by pirmenol (1-30 mol/L) was observed as well in doublemicroelectrode voltage-clamp studies on multicellular tissue preparations of rabbit SA node and Purkinje fibers. 93, 108 In single rabbit atrial myocytes, pirmenol was shown to cause a concentration-dependent decrease in the 4-aminopyridine (4-AP)-sensitive transient outward current (ito), with an IC50 of 10 mol/L. 109 Nakajima et al have suggested that the pirmenol-induced APD prolongation in atrial cells is mediated primarily by ito inhibition, and in atrial myocytes, iK1 was unaffected by pirmenol. 109 Pirmenol also suppressed both iK,ACh and adenosine (Ado)-induced K + currents (iK,Ado) in guinea pig atrial cells with IC50 at about 1 mol/L and 8 mol/L, respectively. 109 The outward current activated by internal loading with GTPgS also was inhibited by pirmenol, with IC50 being 8 mol/L. 109 These data suggest that pirmenol inhibits muscarinic K + currents in atrial myocytes through dual mechanisms: both through blockade of muscarinic receptors and through direct inhibition of the muscarinic K + channel itself and/or the function of GTP-binding protein coupled to the channel. 109 
Receptors and Pumps
No experimental evidence suggests that pirmenol has any action blocking -or -adrenergic receptors. 96, 110 Pirmenol has no significant direct effects on vascular smooth muscle, nor does it alter responses to a variety of agonists. 110 Pirmenol has anticholinergic effects. The potency of pirmenol to antagonize carbachol-induced contraction of the isolated guinea pig ileum was significantly less than that of disopyramide (25% antagonism) or quinidine (50% antagonism). 110 In contrast, the potency of pirmenol to antagonize the negative inotropic effect of carbachol in the guinea pig left atrium was greater than that of disopyramide, with pA2 values being 6.47 and 5.99, respectively. 111 This could reflect different affinities of pirmenol to different subtypes of muscarinic receptors. 112 Cardiac muscarinic receptors are quite unique because of their single receptor subtype population, specifically M2 receptors. 113 On the other hand, smooth muscle contains a mixture of M2 and M3 receptors, and exocrine glands contain mainly M3 receptors. 113, 114 In binding studies on membrane preparations from guinea pig left atrium, submandibular gland, and urinary bladder smooth muscle using [ 3 H]N-methylscopolamine as a ligand, Endou et al found pirmenol to show only one-seventh the affinity for glandular-type muscarinic receptors (M3) than that of cardiac type muscarinic receptors (M2), while disopyramide and pentisomide had comparable affinities for M3 and M2 receptors. 111, 112 No reports to date have shown significant effects of pirmenol on A1 receptors or the function of sarcolemmal Na/K pumps.
Clinical Effects
Electrophysiologic effects of pirmenol have been evaluated in patients with ventricular arrhythmias. PR, QRS, and QT intervals all are prolonged slightly by oral pirmenol at daily doses of 150-450 mg. 115, 116 Prolongation of the QT interval was attributed largely to prolongation of the JT interval. Effects of pirmenol on sinus rate is similar to that of cibenzoline; that is, when given orally, pirmenol does not affect sinus rate significantly, 115, 116 but the drug increases sinus rate (by 13%), when given intravenously (50 mg initially, then 2.5 mg/min). 117 This modest increase in sinus rate with pirmenol may be due to sympathetic reflexes responding to the negative inotropic effect of the drug. 117 Pirmenol does not reduce EF at daily oral doses up to 500 mg, 118 but it reduces EF after intravenous administration. 117 However, an increase in sinus rate occurrs possibly through sympathetic reflexes, keeping the cardiac index unchanged while EF is depressed after intravenous injection. 117 Mean arterial pressure increases after intravenous injection. 117, 119 Major extracardiac adverse effects include dry mouth and urinary hesitancy, and are largely due to anticholinergic properties. 115 Otherwise, no other serious extracardiac adverse effects have been reported. (Table 1) First, pirmenol has a potent use-dependent inhibitory action on the cardiac sodium channel. From onset and offset kinetics of use-dependent blockade, pirmenol is a slow-kinetic drug, and it may block the sodium channel primarily in the activated state. Second, a Ca 2+ channelinhibitory action of pirmenol remains to be confirmed. Third, pirmenol has K + channel blocking action of moderate potency. The potassium channels affected by pirmenol include both voltage-dependent and ligand-gated channels (iK, ito, iK,ACh). Finally, pirmenol has significant anticholinergic effects on the heart, but its anticholinergic effects on smooth muscle and exocrine glands are relatively weak.
Gambit Profile
Discussion
As the group pursued the task of fitting the pharmacologic profiles of the 4 drugs (aprindine, cibenzoline, pilsicainide, and pirmenol) into the spreadsheet of the Gambit framework, we noticed several problems and limitation in completing the table.
First, no quantitative criteria have been set for grading the potency of drug effects on the molecular targets ('low', 'moderate', and 'high' are used semiquantitatively). Onset and offset kinetics of sodium channel blockade are known to be influenced by experimental conditions such as temperature, external Na + concentrations, drug concentrations, protocols of stimulation, and nonlinear relationships between Vmax and iNa. 104, 120 For drugs showing substantial activation trapping and unblocking, such as disopyramide or pirmenol, a change of the resting membrane potential only by several millivolts could result in a marked alteration of the R from use-dependent blockade. 102, [105] [106] [107] These factors often made it difficult to compare data from different experimental studies.
Second, more than 6 different types of K + channels have been identified in cardiac cells. 52, 121 These include voltagegated channels including the delayed rectifier K + current (iK), the transient outward current (ito), and the inward rectifier K + current (iK1), and ligand-gated channels such as the muscarinic acetylcholine receptor-operated K + current (iK,ACh), the ATP-sensitive K + current (iK,ATP), and the Na + -activated K + current (iK,Na). Further, iK is subdivided into rapidly activating components (iKr and iKur) and a slowly activating component (iKs). Each type of K + channel current plays different roles in the repolarization of action potentials and in pacemaking activity. 52, 121 The physiologic and pathologic significance of these K + channel currents also is different in different cardiac tissues and animal species. 52 The presentation of drug actions on the K + channel in a single column is therefore likely to be insufficient and misleading. Further clarification of the specificity of each antiarrhythmic agent for these K + -channel subtypes appears necessary in applying the Gambit concept to clinical arrhythmias, especially atrial tachyarrhythmias; for example, much information has accumulated about the mechanism of atrial fibrillation, and molecular data relating to atrial remodeling, including modification of expression of various K + channel proteins, have been obtained. [122] [123] [124] [125] Specific K + channels that play a pivotal part in initiating or sustaining atrial fibrillation should be a target of antifibrillatory therapy. We now know that paroxysmal atrial fibrillation is triggered exclusively by enhanced vagal activity that activates iK,ACh and shortens atrial refractory periods. Drugs that inhibit this current either directly or indirectly through muscarinic receptor blocking, such as cibenzoline and pirmenol, promise to be more beneficial in preventing vagally induced paroxysmal atrial fibrillation than disopyramide, which suppresses this current only indirectly. Furthermore, as atrial remodeling with modification of expression of target K + channels progresses, [123] [124] [125] onceeffective drugs may become ineffective.
As shown in Table 1 , we found that cibenzoline and pirmenol, both of which have a pharmacologic profile very similar to that of disopyramide, have different effects on ECG parameters, especially the JT interval. This can be explained in terms of the difference in K + channel subtype specificity; these 3 drugs may have different potencies of action at various K + channels expressed predominantly in the atrium or in the ventricle. Any drugs that selectively prolong atrial refratory periods without QT prolongation should be ideal for treatment of atrial fibrillation. Thus, further investigations are needed to elucidate K + channel subtype specificity for all available agents.
A third problem with the Gambit approach is that clinical effects on LV function, heart rate, and electrocardiographic intervals (PR, QRS, JT) are indicated by arrows (increase, decrease, or no change), and extracardiac sideeffects are presented by 3 symbols (low, moderate, or high). No quantitative criteria on standards for such estimation and grading have been adopted, interfering with data comparison involving different clinical studies with different protocols. Despite these limitations, we noted that unlike other Na + channel blockers with slow recovery kinetics, pilsicainide has a relatively minimal effect on LV function, permitting administration to patients with LV impairment.
In addition, the Gambit framework does not discriminate between acute and chronic effects of antiarrhythmic drugs, which could distort or limit profiling of some drugs. For instance, long-term administration of amiodarone for several weeks is known to cause quite different effects on ion channels, receptors, pumps, electrocardiographic parameters, and extracardiac organs than those immediately following initial administration of the drug. 126 Despite such problems and limitations, the group's task was no doubt worthwhile. The Guideline Committee members include selected experts on arrhythmias from Japan having different specialties including molecular and cellular electrophysiology, in vivo experimental cardiology, and clinical cardiology. This diversity facilitated extensive discussion of the pharmacologic profiles of the 4 drugs from different viewpoints and perspectives to reach a balanced conclusion. We have identified essential data and information that still are lacking but are required to outline the fundamental profiles of the 4 drugs. The continuing discussion will direct urgently needed experimental and clinical studies.
